Skip to Main Content

Endocrinology & Metabolism Newsletter

May 2024

Dear Colleagues,

With spring underway, research programs in the Section of Endocrinology and Metabolism continue to flourish. In this newsletter, we highlight ways to reverse insulin resistance, the relationship between the brain and obesity, the cost of novel diabetes and obesity medications, and more. We also learn some fun—and surprising—facts about Richard Kibbey, MD, PhD, and Mireille Serlie, MD, PhD, who reflect on their careers as recently promoted/appointed professors!

I hope you enjoy reading about a few of the many ways we are helping patients by being at the forefront of discovery. As always, please feel free to contact me at the email address below to share your news for possible inclusion in a future newsletter.


John Wysolmerski, MD
Professor of Medicine (Endocrinology)
Section Chief, Endocrinology & Metabolism
Department of Internal Medicine, Yale School of Medicine

Latest News

Curbing the Price of Novel Diabetes and Obesity Medications

For years, Yale School of Medicine's Kasia Lipska, MD, MHS, has been advocating for affordable pricing of insulin, an essential —and sometimes lifesaving—drug for many individuals with diabetes. Now, she is turning her attention to a similar trend of soaring prices among new diabetes and obesity medications.

Read more
  • How to Reverse Insulin Resistance

    In a Q&A, Gerald I. Shulman, MD, PhD, George R. Cowgill Professor of Medicine (Endocrinology) and professor of cellular and molecular physiology, discusses the basics of insulin resistance, how the condition impacts our health, and the steps we can take to reverse it.

    Read more
  • How the Standard American Diet Affects Your Brain

    In a Q&A, Mireille Serlie, MD, PhD, discusses the effects of eating patterns on the brain, the risks of being frequently exposed to high-sucrose and high-fat foods, and recommendations for adopting healthy eating habits.

    Read more
  • Glycemic Control and Risk of Complications in Older Adults with Type 2 Diabetes

    Hemoglobin A1c (HbA1c) level plays an important role in type 2 diabetes (T2D) treatment, serving as an important indicator of an individual’s glucose control. The Endocrine Society has outlined specific HbA1c target ranges for older adults (above 65 years of age), based on their individual health status as being either in good, intermediate, or poor health.

    Read more
Get RSS Feed